文献速递角膜与眼表疾病青光眼

无虹膜患者植入波士顿1型人工角膜后的青光眼管理

Glaucoma Management in Patients With Aniridia and Boston Type 1 Keratoprosthesis.
PubMed 文献 · Am J Ophthalmol · 2019-06-24

回顾性介入比较病例系列研究,纳入在马萨诸塞眼耳医院接受波士顿1型人工角膜(KPro)植入且随访至少2年的无虹膜患者(22眼)与其他术前诊断患者(61眼)。无虹膜组术前青光眼比例(76.2%)和青光眼手术史(57.1%)高于对照组(51.8%、23.2%),术中联合植入Ahmed阀的比例更高(47.6% vs 17.9%)。尽管随访期末无虹膜组青光眼比例更高(90.5% vs 64.3%),两组视力改善和最终视力相似。

要点

  • 无虹膜组术前青光眼比例76.2%,高于对照组51.8%(P = .053)。
  • 无虹膜组联合植入Ahmed阀比例47.6%,高于对照组17.9%(P = .008)。
  • 预防性植入引流管的患眼均未发展为青光眼。

核心结论

  • 尽管无虹膜眼青光眼患病率更高,在平均随访超过5年的情况下,无虹膜眼获得了与对照眼相似的视力。
  • 在积极管理青光眼的前提下,波士顿KPro可为无虹膜患者提供满意的视力康复。

研究设计与样本

  • 回顾性、介入性比较病例系列研究。
  • 纳入在马萨诸塞眼耳医院接受KPro植入且随访至少2年的无虹膜患者和其他术前诊断患者(排除Stevens-Johnson综合征、黏膜类天疱疮和先天性疾病)。
  • 无虹膜组22眼,对照组61眼;每例患者选择随访时间较长的一只眼。
  • 主要结局为与青光眼相关的中期和长期结局。

主要发现

  • 无虹膜组与对照组术前视力相似(平均值±标准差,1.86 ± 0.52 logMAR,P = .33),随访时间相似(65.6 ± 26.3个月,P = .25)。
  • KPro植入前,无虹膜组青光眼比例76.2%,对照组51.8%(P = .053);无虹膜组青光眼手术史57.1%,对照组23.2%(P = .005)。
  • 无虹膜组联合植入Ahmed阀比例47.6%,对照组17.9%(P = .008)。
  • 随访期末,无虹膜组青光眼比例90.5%,对照组64.3%(P = .02);两组杯盘比(CDR)>0.8的比例分别为23.8% vs 30.4%(P = .57),CDR进展≥0.2的比例分别为42.9% vs 44.6%(P = .89)。
  • 预防性植入引流管的患眼均未发展为青光眼;两组KPro术后视力改善比例分别为72.7% vs 72.1%(P = .96),最终视力分别为1.28 ± 0.79 logMAR vs 1.23 ± 0.98 logMAR(P = .51)。

临床怎么用

  • 原文结论指出,在积极管理青光眼的前提下,波士顿KPro可为无虹膜患者提供满意的视力康复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess outcomes and glaucoma management in eyes with aniridia following Boston type 1 Keratoprosthesis (KPro) implantation. DESIGN: Retrospective, interventional comparative case series. METHODS: The population included patients with aniridia and patients with other preoperative diagnoses (excluding Stevens-Johnson syndrome, mucous membrane pemphigoid, and congenital disorders) who underwent KPro implantation at Massachusetts Eye and Ear with at least 2 years of follow-up. One eye per patient was selected based on the longer follow-up time. The main outcome was intermediate and long-term outcomes related to glaucoma. RESULTS: The aniridia (n = 22) and comparison (n = 61) groups had similar preoperative visual acuity (VA, mean ± standard deviation, 1.86 ± 0.52 logMAR, P = .33) and follow-up time (65.6 ± 26.3 months, P = .25). Before KPro implantation, eyes with aniridia had more glaucoma (76.2%) and glaucoma surgery (57.1%) than comparison eyes (51.8%, P = .053; 23.2%, P = .005, respectively). More Ahmed valves were co-implanted with KPro in aniridia (47.6%) vs comparison eyes (17.9%, P = .008). At final follow-up, more aniridia eyes had glaucoma (90.5%) than comparison eyes (64.3%, P = .02), but the 2 groups had similar percentages of eyes with cup-to-disc ratio (CDR) >0.8 (23.8% vs. 30.4%, P = .57) or CDR progression of ≥0.2 (42.9% vs 44.6%, P = .89, respectively). None of the eyes with prophylactic tube implantation developed glaucoma. Eyes with and without aniridia did not differ in post-KPro VA improvement (72.7%, 72.1%, P = .96), and final VA (1.28 ± 0.79 logMAR, 1.23 ± 0.98 logMAR, P = .51). CONCLUSION: Despite a higher glaucoma prevalence, eyes with aniridia achieved similar VA as comparison eyes with more than 5 years of mean follow-up time. Boston KPro offers satisfactory visual rehabilitation in aniridia when glaucoma is managed aggressively.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Nascimento E Silva R, Shen LQ, Chiou CA, et al. Glaucoma Management in Patients With Aniridia and Boston Type 1 Keratoprosthesis. Am J Ophthalmol. 2019. PMID: 31247168. doi:10.1016/j.ajo.2019.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。